1. Home
  2. MRKR vs BAFN Comparison

MRKR vs BAFN Comparison

Compare MRKR & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.45

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$6.48

Market Cap

26.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
BAFN
Founded
1999
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
26.6M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
MRKR
BAFN
Price
$1.45
$6.48
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
62.1K
73.4K
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
1.00%
EPS Growth
33.61
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$936.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$4.80
52 Week High
$4.07
$16.35

Technical Indicators

Market Signals
Indicator
MRKR
BAFN
Relative Strength Index (RSI) 45.93 43.75
Support Level $1.34 $6.40
Resistance Level $1.52 $7.08
Average True Range (ATR) 0.07 0.54
MACD -0.01 -0.10
Stochastic Oscillator 21.74 23.67

Price Performance

Historical Comparison
MRKR
BAFN

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: